Skip to content

ICG Indocyanine Green in Reconstructive Surgery

Determining Critical Thresholds of Tissue Perfusion With ICG in Reconstructive Surgery

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06129669
Acronym
ICG-R
Enrollment
160
Registered
2023-11-13
Start date
2023-05-09
Completion date
2025-05-31
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fluorescence, Surgery

Keywords

Reconstructive surgery, Free flap, Pedicled flap, Debridement, Fluorescence imaging, Indocyanine green

Brief summary

The success or failure of a reconstruction is largely related to the vascularization of the operated area. Near infrared fluorescence (also near infrared fluorescence angiography, NIR FA) with ICG administration is an innovative technique to quantify tissue perfusion. Based on the results obtained in other subspecialties, NIR fluorescence appears to be a promising way to quantify tissue perfusion in reconstructive surgery. Fluorescence research has previously been used in the context of microsurgery and breast reconstructions using implants, but structural objective determinations are lacking. Our study is successful if we are able to determine a cut off value for the absolute or relative perfusion parameters.

Interventions

DRUGIndocyanine green

Administration of ICG during surgery and recording of the fluorescence video to perform data analyses

Sponsors

Amsterdam UMC, location VUmc
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 110 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 18 or older * Undergoing debridement and/or reconstructive surgery included in the aforementioned groups

Exclusion criteria

* allergy or hypersensitivity to sodium iodide, iodine, ICG or shellfish * patients with hyperthyroidism and patients with autonomic thyroid adenoma * pregnancy or lactation * epilepsy * severe liver failure * renal failure with a GFR \<60.

Design outcomes

Primary

MeasureTime frameDescription
Maximum perfusion intensity (Normal)Once during the surgery1\. Maximum perfusion intensity (Imax, units) in a normal vascularized reference frame
Maximum perfusion intensity (ROI)Once during the surgery2\. Maximum perfusion intensity (Imax, units) in a normal vascularized reference frame
Relative PerfusionOnce during the surgeryMaximum perfusion intensity (Imax, units) in a normal vascularized reference frame / Maximum perfusion intensity (Imax, units) in a normal vascularized reference frame

Secondary

MeasureTime frameDescription
Lap FailureFollow up at six weeks postoperativeQuantified as I \<5%; II 5-15%, III 15-50%, IV\> 50%, V complete
Wound infectionFollow up at six weeks postoperativeDefined as none, local wound treatment, antibiotics, or hospitalization.
TmaxOnce during the surgeryTime to reach maximum perfusion in region of interest (Tmax, sec)
Delayed unionFollow up at six and twelve months postoperativeRadiologic examination (Xray or CT) concluding on the presence of delayed union after 6 months or non-union after 12 months
Relative Perfusion before and after tissue transferTwice during the surgeryMaximum perfusion intensity (Imax, units) in the same reference frame after tissue transfer / Maximum perfusion intensity (Imax, units) in a reference frame before tissue transfer
Skin necrosisFollow up at six weeks postoperativeDefined as none, partial thickness, and full thickness.
IngressOnce during the surgeryRate of increase in intensity from baseline to peak intensity (Ingress, units)
EgressOnce during the surgeryDegree of decrease in intensity from peak to last measurement (Egress, units)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026